OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Feldman on Study of Active Surveillance in Younger Men With Prostate Cancer

September 6th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses a study of active surveillance in younger men with prostate cancer.

Dr. Rosenberg Discusses the Importance of Clinical Trials in Bladder Cancer

September 6th 2017

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

Dr. Kumar Discusses Study of Ixazomib in Multiple Myeloma

September 6th 2017

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

Dr. Byrd on Impact of Ibrutinib on Patients With CLL

September 6th 2017

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the long-term impact that ibrutinib (Imbruvica) has on patients with chronic lymphocytic leukemia (CLL).

Dr. Badani on Determining Which Patients With RCC Will Receive Robotic Surgery

September 6th 2017

Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses how to determine which patient with renal cell carcinoma (RCC) will benefit from robotic surgery.

Dr. Voorhees on Managing TRAEs for Patients With Multiple Myeloma

September 6th 2017

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses optimal management of treatment-related adverse events (TRAEs) for patients with multiple myeloma.

Dr. Barber on SCORPION Trial in Ovarian Cancer

September 6th 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses the importance of the SCORPION trial in ovarian cancer.

Dr. Brawer on the Results of the Prolaris Test for Patients Prostate Cancer

September 6th 2017

Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the results of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

Dr. Lallas on Understanding Immunotherapy in GU Malignancies

September 6th 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.

Dr. Taieb Discusses Primary Tumor Location in CRC

September 6th 2017

Julien Taieb, MD, head of the gastroenterology and gastrointestinal oncology department of the Georges Pompidou European Hospital, Paris Descartes University, discusses primary tumor location in colorectal cancer.

Dr. Vokes on the Standard of Care for Stage III NSCLC

September 1st 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses the standard of care for patients with stage III non

Dr. Riess on the Long-Term Benefit With Immunotherapy for Lung Cancer

September 1st 2017

Jonathan Riess, MD, assistant professor of medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses the long-term benefit with immunotherapy for patients with lung cancer.

Dr. Pegram on Challenges Facing the Treatment of HER2-Positive Breast Cancer

September 1st 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses challenges facing the treatment of patients with HER2-positive breast cancer.

Dr. Holmes on Neoadjuvant Endocrine Therapy in Breast Cancer

September 1st 2017

Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant endocrine therapy for patients with breast cancer.

Dr. Furman on Exciting Available Agents for Patients With CLL

September 1st 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the available agents that have shown promise for patients with chronic lymphocytic leukemia (CLL).

Dr. Martin on Potential for CAR T-Cell Therapy in MCL Landscape

September 1st 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the landscape of mantle cell lymphoma (MCL).

Dr. Chiang on Toxicities with Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

September 1st 2017

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the toxicities with ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).

Dr. Kaouk on Benefits of Robotic Partial Nephrectomy for RCC

September 1st 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses the benefits of robotic partial nephrectomy for patients with renal cell carcinoma (RCC).

Dr. Higano on the Effectiveness of PARP Inhibitors for Prostate Cancer

September 1st 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.

Dr. Garon on Antiangiogenic Agents in Lung Cancer

September 1st 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.